🔒
Price chart and 15 days of daily prices
Candlestick chart with moving averages, Bollinger bands and MACD.
Register free to view.
Security Profile
- Security Type
- Common Stock
- CUSIP
- 046513206 (prev. 046513107 )
- Market Cap
- Large Cap
- IPO
- 10/15/2014 · $11.00/share
Business: Atara Biotherapeutics, Inc. is a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases. Atara’s technology platform leverages research collaborations with leading academic institutions with the Company’s scientific, clinical, regulatory and manufacturing expertise.
Notes: June 20, 2024, Atara Biotherapeutics, Inc., a Delaware corporation (the “Company”), effected a one-for-twenty-five (1:25) reverse stock split (the “Reverse Stock Split”) of the Company’s common stock, par value $0.0001 per share On June 20, 2024, the Common Stock began trading on a split-adjusted basis under a new CUSIP number, 046513206.
Company Contact
- CEO
- Pascal Touchon
- CFO
- Utpal Koppikar
- Headquarters
- 611 Gateway Blvd., Suite 900, South San Francisco, CA 91320
- Phone
- 805-623-4211
- Investor Relations
- Jason Awe · 650-410-3012 · jawe@atarabio.com